Vancomycin-resistant Staphylococcus aureus overview

Revision as of 19:07, 18 September 2017 by WikiBot (talk | contribs) (Changes made per Mahshid's request)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Vancomycin-resistant Staphylococcus aureus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Vancomycin-resistant Staphylococcus aureus overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vancomycin-resistant Staphylococcus aureus overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vancomycin-resistant Staphylococcus aureus overview

CDC on Vancomycin-resistant Staphylococcus aureus overview

Vancomycin-resistant Staphylococcus aureus overview in the news

Blogs on Vancomycin-resistant Staphylococcus aureus overview

Directions to Hospitals Treating Vancomycin-resistant Staphylococcus aureus

Risk calculators and risk factors for Vancomycin-resistant Staphylococcus aureus overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Vancomycin-resistant Staphylococcus aureus (VRSA) is a strain of Staphylococcus aureus that has become resistant to the glycopeptide antibiotic vancomycin. With the increase of staphylococcal resistance to methicillin, vancomycin (or teicoplanin) is often a treatment of choice in infections with methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin resistance is still a rare occurrence. Unfortunately, VRSA may also be resistant to meropenem and imipenem, two other antibiotics that can be used in sensitive staphylococcus strains. Even with the absence of high-level resistance to vancomycin, another concern posed by the presence of VISA (vancomycin-intermediate Staphylococcus aureus) is the increased difficulty in prescribing treatments, especially in situations where an effective treatment for an infection is needed urgently, before detailed resistance profiles can be obtained. In hospitals already endemic with multiresistant MRSA, the appearance of VRSA would make the treatment of infected patients much more difficult. At present, high-level resistances to both glycopeptide and β-lactam antibiotics in Staphylococcus aureus seem to be mutually exclusive, in that both resistances are not seen at once in the same strain of bacterium. However, this is not due to a fundamental biochemical incompatibility. Theoretically, a superbug displaying high-level resistances to both classes of antibiotics could evolve given the current selective environment. VISA and VRSA are specific types of antimicrobial-resistant staph bacteria. While most staph bacteria are susceptible to the antimicrobial agent vancomycin, some have developed resistance.

Historical Perspective

VISA (vancomycin-intermediate Staphylococcus aureus) was first identified in Japan in 1996 and has since been found in hospitals in England, France, the U.S., Asia and Brazil. It is also termed GISA (glycopeptide-intermediate Staphylococcus aureus) indicating resistance to all glycopeptide antibiotics. These bacterial strains present a thickening of the cell wall which is believed to deplete the vancomycin available to kill the bacteria.

Causes

VISA and VRSA are specific types of antimicrobial-resistant Staphylococcus aureus. Staphylococcus aureus, often simply referred to as “staph”, are bacteria commonly found on the skin and in the nose of healthy people. Occasionally, they can cause infection and they are one of the most common causes of skin infections in the United States.

Epidemiology and Demographics

VISA and VRSA infections are rare. Only sixteen cases of infection caused by VISA (Michigan 1997, New Jersey 1997, New York 1998, Illinois 1999, Minnesota 2000, Nevada 2000, Maryland 2000, and Ohio 2001) and six cases of infection caused by VRSA (Michigan 2002 , Pennsylvania 2002, New York 2004, and 3 from Michigan in 2005) have been reported in the United States.

Risk Factors

Persons with underlying health conditions (such as diabetes and kidney disease), previous infections with methicillin-resistant Staphylococcus aureus (MRSA), tubes going into their bodies (such as intravenous catheters), recent hospitalizations, and recent exposure to vancomycin and other antimicrobial agents are at increased risk of developing VISA and VRSA infections.

Diagnosis

Laboratory Findings

Staph bacteria are classified as VISA or VRSA based on laboratory tests. Laboratories perform tests to determine if staph bacteria are resistant to antimicrobial agents that might be used for treatment of infections. For vancomycin and other antimicrobial agents, laboratories determine how much of the agent it requires to inhibit the growth of the organism in a test tube. The result of the test is usually expressed as a minimum inhibitory concentration (MIC) or the minimum amount of antimicrobial agent that inhibits bacterial growth in the test tube. Therefore, staph bacteria are classified as VISA if the MIC for vancomycin is 4-8µg/ml, and classified as VRSA if the vancomycin MIC is >16µg/ml.

Treatment

Medical Therapy

VISA and VRSA cannot be successfully treated with vancomycin because these organisms are no longer susceptibile to vancomycin. However, to date, all VISA and VRSA isolates have been susceptible to other Food and Drug Administration (FDA) approved drugs like trimethoprim/sulfamethoxazole, clindamycin, or ceftaroline.

Primary Prevention

Use of appropriate infection control practices (such as wearing gloves before and after contact with infectious body substances and adherence to hand hygiene) by healthcare personnel can reduce the spread of VISA and VRSA.

References

Template:WH Template:WS